Home  >  Pharma People
Pharma People
+ Font Resize -

Neurotrope appoints Charles S. Ryan as CEO

New York
Tuesday, December 19, 2017, 18:00 Hrs  [IST]

Neurotrope, a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced the appointment of Charles S. Ryan, JD, PhD as chief executive officer and Director. The appointment follows the resignation of Susanne Wilke, PhD, as chief executive officer and Director.

Dr. Ryan becomes a director of the company effective immediately and will assume his responsibilities as CEO effective February 15, 2018.

Dr. Ryan brings with him an extensive background in pharmaceuticals and biotechnology. Most notably, he served as senior vice president and chief intellectual property counsel at Forest Laboratories for more than 10 years, where he managed several intellectual property estates, including participating in the development and commercial launch of Namenda (memantine HCL), a blockbuster drug for the treatment of AD that generated peak sales of approximately $1.5 billion in 2014. Dr. Ryan worked closely with the commercial and development teams as well as experts in the field, establishing a strong network in the AD space.

“We are excited to have Dr. Ryan join our team. His experience in late-stage drug development and commercialization in the Alzheimer’s disease space, combined with his track record of successful strategic transactions, will help guide the further development of bryostatin for a range of neurodegenerative disorders,” said Joshua Silverman, chairman of the board of directors at Neurotrope. “We accept the resignation of Dr. Wilke and thank her for her services to the Company as Chief Executive Officer and Director. As Chief Executive Officer, she led the restructuring that established the foundation on which the Company can build and advance to the next level. We wish her well in her future endeavors.”

“The fundamental science behind Neurotrope’s lead drug candidate, bryostatin, is very solid,” said Dr. Ryan. “The compound’s unique mechanism of action represents one of the most promising therapeutic approaches to not only slow cognitive decline, but actually improve cognition in patients with advanced Alzheimer’s disease, a patient population that is extremely difficult to treat. I look forward to working with my new colleagues at Neurotrope to advance the development of bryostatin for Alzheimer’s disease and other neurodegenerative disorders.”

Dr. Ryan is currently president and chief executive officer of Orthobond Corporation where he is responsible for all aspects of the company’s daily operations and works closely with the Board of Directors developing the short and long term strategic plans for the company. Dr. Ryan has negotiated several partnership, financing and licensing agreements. After leaving Forest Laboratories and prior to joining Orthobond, Dr. Ryan served as vice president, General Counsel for Cold Spring Harbor Laboratory. In this role at Cold Spring, he provided guidance on business, legal and public policy issues, including licensing, patenting, partnerships, alliances, compliance and regulatory matters. Dr. Ryan currently serves on the Board of two public companies, Applied DNA Sciences, Inc. and BioRestorative Therapies, Inc. as well as Orthobond, Inc. He also serves on the Board of Trustees of The College of Wooster. He holds a BA in Chemistry from The College of Wooster, a PhD in Oral Biology and Pathology from Stony Brook University and a JD from Western New England University.

 

Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
duphat_150x60
IPJPI18_150x60en_2018
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |